These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37541828)

  • 1. Neuroendocrine insights into neurosteroid therapy for postpartum depression.
    Reddy DS
    Trends Mol Med; 2023 Dec; 29(12):979-982. PubMed ID: 37541828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy.
    Reddy DS; Mbilinyi RH; Estes E
    Psychopharmacology (Berl); 2023 Sep; 240(9):1841-1863. PubMed ID: 37566239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [GABAergic approach of postpartum depression: A translational review of literature].
    Verbe J; Dubertret C; El-Hage W; Bonnet-Brilhault F; Duriez P
    Encephale; 2020 Apr; 46(2):123-134. PubMed ID: 31767256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience.
    Lüscher B; Möhler H
    F1000Res; 2019; 8():. PubMed ID: 31275559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women.
    Reddy DS
    J Neuroendocrinol; 2022 Feb; 34(2):e13028. PubMed ID: 34506047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care.
    Jarman AF; MacLean JV; Barron RJ; Wightman RS; McGregor AJ
    Clin Ther; 2020 Jan; 42(1):231-235. PubMed ID: 31910998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent Transcriptomic Effects of Allopregnanolone in Postpartum Depression.
    Rudzinskas SA; Mazzu MA; Schiller CE; Meltzer-Brody S; Rubinow DR; Schmidt PJ; Goldman D
    Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of neuroactive steroids for the treatment of postpartum depression.
    Gunduz-Bruce H; Takahashi K; Huang MY
    J Neuroendocrinol; 2022 Feb; 34(2):e13019. PubMed ID: 34462985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anxiolytic and Anti-depressive Like Effects of Translocator Protein (18 kDa) Ligand YL-IPA08 in a Rat Model of Postpartum Depression.
    Ren P; Ma L; Wang JY; Guo H; Sun L; Gao ML; Liu YZ; Ma YQ; Li YF; Guo WZ
    Neurochem Res; 2020 Aug; 45(8):1746-1757. PubMed ID: 32383026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical review and recommendations for enhancement of the article on novel neurosteroid therapeutics for postpartum depression.
    Ribeiro TT; de Araújo MB; Nogueira GN; de Matos E Souza FG; Bisol LW
    Neuropsychopharmacology; 2024 Jun; 49(7):1065-1066. PubMed ID: 38472277
    [No Abstract]   [Full Text] [Related]  

  • 11. Brexanolone for postpartum depression.
    Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF
    Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiological markers of rapid antidepressant effects of allopregnanolone.
    Lambert PM; Lu X; Zorumski CF; Mennerick S
    J Neuroendocrinol; 2022 Feb; 34(2):e13023. PubMed ID: 34423498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postpartum Depression: Identification and Treatment in the Clinic Setting.
    Kroska EB; Stowe ZN
    Obstet Gynecol Clin North Am; 2020 Sep; 47(3):409-419. PubMed ID: 32762926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions.
    Patterson R; Balan I; Morrow AL; Meltzer-Brody S
    Neuropsychopharmacology; 2024 Jan; 49(1):67-72. PubMed ID: 37715106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexanolone to Treat Postpartum Depression in Adult Women.
    Cornett EM; Rando L; Labbé AM; Perkins W; Kaye AM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2021 Mar; 51(2):115-130. PubMed ID: 34092826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.
    Chuang SH; Reddy DS
    J Pharmacol Exp Ther; 2020 Mar; 372(3):285-298. PubMed ID: 31843812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.
    Leader LD; O'Connell M; VandenBerg A
    Pharmacotherapy; 2019 Nov; 39(11):1105-1112. PubMed ID: 31514247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroactive steroids - new possibilities in the treatment of postpartum depression.
    Žigová L; Massarová P; Vranecová K; Hrubá O; Adamičková A; Gažová A
    Ceska Slov Farm; 2022; 71(4):142-150. PubMed ID: 36208918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating brexanolone for the treatment of postpartum depression.
    Payne JL
    Expert Opin Pharmacother; 2021 Jun; 22(8):959-964. PubMed ID: 33645386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression.
    Powell JG; Garland S; Preston K; Piszczatoski C
    Ann Pharmacother; 2020 Feb; 54(2):157-163. PubMed ID: 31476884
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.